Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/cpt.1010 http://scihub22266oqcxt.onion/10.1002/cpt.1010 C5947521!5947521 !29315510     free     free     free       Clin+Pharmacol+Ther 2018 ; 103 (5 ): 802-814 Nephropedia Template TP {{tp|p=29315510 |t=2018. Developing Drugs for Heart Failure With Reduced Ejection Fraction: What Have We Learned From Clinical Trials? |pdf=|usr=}}{{29315510 }} gab.com Text Developing Drugs for Heart Failure With Reduced Ejection Fraction: What Have We Learned From Clinical Trials JO: Clin Pharmacol Ther http://www.kidney.de/pget.php?&tw=1&pmid=29315510 #FOAvip There remains a large unmet need for new therapies in the treatment of heart failure with reduced ejection fraction (HFrEF). In the early drug development phase, the therapeutic potential of a drug is not yet fully understood and trial endpoints other than mortality are needed to guide drug development decisions. While a true surrogate marker for mortality in heart failure (HF) remains elusive, the successes and failures of previous trials can reveal markers that support clinical Go/NoGo decisions. Twit Text FOAVip Developing Drugs for Heart Failure With Reduced Ejection Fraction: What Have We Learned From Clinical Trials ????Clin Pharmacol Ther http://www.kidney.de/pget.php?&tw=1&pmid=29315510 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29315510 #FOAvip English Wikipedia <ref>{{Cite pmid|29315510 }}</ref> Developing Drugs for Heart Failure With Reduced Ejection Fraction: What Have We Learned From Clinical Trials? #MMPMID29315510 Hinder M ; Yi BA ; Langenickel TH Clin Pharmacol Ther 2018[May]; 103 (5 ): 802-814 PMID29315510 show ga There remains a large unmet need for new therapies in the treatment of heart failure with reduced ejection fraction (HFrEF). In the early drug development phase, the therapeutic potential of a drug is not yet fully understood and trial endpoints other than mortality are needed to guide drug development decisions. While a true surrogate marker for mortality in heart failure (HF) remains elusive, the successes and failures of previous trials can reveal markers that support clinical Go/NoGo decisions. |Biomarkers/metabolism [MESH] |Clinical Trials as Topic [MESH] |Drug Development/methods [MESH] |Heart Failure/*drug therapy/metabolism [MESH] |Heart/*drug effects [MESH] |Humans [MESH]Developing Drugs for Heart Failure With Reduced Ejection Fraction: Wha(epmc).pdf DeepDyve Pubget Overpricing